Humacyte, Inc. (HUMA)
NASDAQ: HUMA · Real-Time Price · USD
0.5744
-0.0046 (-0.79%)
Sep 10, 2026, 1:51 PM EDT - Market open
Humacyte Employees
Humacyte had 184 employees as of December 31, 2025. The number of employees decreased by 36 or -16.36% compared to the previous year.
Employees
184
Change (1Y)
-36
Growth (1Y)
-16.36%
Revenue / Employee
$11,527
Profits / Employee
-$525,370
Market Cap
159.57M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 184 | -36 | -16.36% | 184 | 0 |
| Dec 31, 2024 | 220 | 35 | 18.92% | 218 | 2 |
| Dec 31, 2023 | 185 | 21 | 12.80% | 183 | 2 |
| Dec 31, 2022 | 164 | 18 | 12.33% | 164 | 0 |
| Dec 31, 2021 | 146 | - | - | 145 | 1 |
Related Stocks
| Company Name | Employees |
|---|---|
| LENZ Therapeutics | 152 |
| Codexis | 146 |
| Molecular Partners AG | 134 |
| MediWound | 121 |
| Immunic | 100 |
| Caribou Biosciences | 97 |
| Milestone Pharmaceuticals | 38 |
| Jyong Biotech | 27 |
HUMA News
- 5 hours ago - Humacyte to Present at the H.C. Wainwright 28th Annual Global Investment Conference - GlobeNewsWire
- 1 day ago - Humacyte announces FDA extension of expiration dating period for Symvess - TheFly
- 1 day ago - Humacyte Announces FDA Authorization Extending Symvess Shelf Life to 36 Months - GlobeNewsWire
- 5 days ago - Humacyte Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Humacyte, Inc. - HUMA - Business Wire
- 17 days ago - Humacyte confirms plans for ATEV supplemental biologic license application - TheFly
- 17 days ago - Humacyte Confirms Plans for ATEV Supplemental BLA Filing for Dialysis Access Following FDA Discussions - GlobeNewsWire
- 22 days ago - Humacyte publishes V007 results in The Lancet Digital Health - TheFly
- 22 days ago - Humacyte Announces Lancet Digital Health Publication of V007 Phase 3 Hemodialysis Access Trial Results - GlobeNewsWire